The Federal Trade Commission is continuing its fight against alleged anti-competitive behavior in the U.S. pharmaceutical industry by pushing for federal legislation that would bar makers of brand-name prescription drugs from paying generic drug manufacturers to delay a generic drug release.
The agency said the sharp rise of such anti-competitive settlements between the two types of drug makers deprives consumers of affordable prescription drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]